Navigation Links
International event brings world's top cancer doctors to Queen's
Date:9/1/2009

Over 200 of the world's top cancer specialists will be in Belfast this week to share their knowledge at an International Cancer Symposium organised by Queen's University.

The event, being hosted by the Centre for Cell Biology and Cancer Research (CCRCB) on Wednesday and Thursday, will be attended by leading academics from across America, Australia and Europe, including those from Harvard Medical School in Boston and from Oxford and Cambridge universities.

One in three people in Northern Ireland will be diagnosed with cancer at some stage in their life and the conference aims to build on international links to improve cancer treatments for sufferers.

CCRCB is currently carrying out around 50 national and international clinical trials into various cancers with the aim of offering patients new treatment options which will have the best outcomes for them as well as fewer and less severe side effects.

The Centre has three successful spin-out companies - ALMAC Diagnostics, Fusion Antibodies and I-Path - employing nearly 200 people.

Two young researchers will present their studies at the event entitled 'Cancer: Found in Translation'.

Dr Kelly Redmond from Newry and Dr Jenny Quinn from Londonderry will be among the international line-up of speakers sharing their knowledge about the latest developments in cancer research.

Dr Redmond will speak about her research into a molecule called FLIP which blocks chemotherapy from working in non-small cell lung cancer (NSCLC), the leading cause of cancer death in the US and Europe. By decreasing FLIP levels in NSCLC cells they become more sensitive to chemotherapy.

She said: "This is an important finding as it suggests that if we can decrease FLIP levels with new types of drugs, the cancer but not the normal lung tissues will be more effectively killed by chemotherapy."

Dr Quinn's research has focused on trying to find the best chemotherapy treatment for both breast and ovarian cancer sufferers.

She has investigated the effects of the drugs on patients with and without the BRCA1 gene, which controls cell growth in normal breast and ovarian cells, preventing tumours forming.

Ovarian cancer patients are generally treated with both platinum and taxane based chemotherapy. However Dr Quinn has found that patients without BRCA1 benefited significantly from platinum only chemotherapy while those with normal BRCA1 levels gained an almost two year improvement in survival if they also received taxane chemotherapy.

Dr Quinn said: "We are now planning further studies that may ultimately lead to the development of a test involving BRCA1 for determining the best chemotherapy treatments for patients with ovarian cancer. Such a test may also prove useful in breast, lung and prostate cancer."

The symposium has been organised by Professor Dennis McCance, Director of the Centre for Cancer Research and Cell Biology at Queen's University, who leads a team of around 250 staff.

He said: "This event reflects CCRCB's achievements in cancer research and highlights our aspirations to see our knowledge about basic research translated into better and more effective treatments for patients.

"Through clinical trials we are working to offer patients new treatment options which will have the best outcomes for them.

"We are using novel ways to select treatments and personalise or tailor them to the patient's particular mutations.

"The calibre of speakers coming to our conference and the international links that we have formed demonstrate that our work is considered of a world-class standard."

Professor Peter Gregson, Vice-Chancellor of Queen's University, said: Cancer is a disease feared around the world. Its impact is global. It therefore demands a global response, a response where leading researchers work together across academic disciplines and geographical frontiers.

"We are pleased to bring together leading academics and researchers from across the world to discuss innovative scientific and medical research that will help those who suffer from cancer."


'/>"/>

Contact: Andrea Clements
a.clements@qub.ac.uk
Queen's University Belfast
Source:Eurekalert

Related biology news :

1. Forest Service to host 2nd International Conference on Forests and Water in a Changing Environment
2. EMBO pioneers pension plan for internationally mobile postdoctoral researchers
3. International conference on CO2 sequestration processes
4. International research team seeks to unravel flatworm regeneration
5. Fujitsu PalmSecure Certified Under International Common Criteria Evaluation Assurance Level 2
6. Journal of Vascular and Interventional Radiology increases impact, international reach
7. International team of students and scientists on month-long field course in Siberian Arctic
8. ESHRE launches international study of polar body screening
9. International collaboration by scientists culminates in novel ion channels database
10. Susan E. Gardiner receives ASHS Outstanding International Horticulturist Award
11. SRI International announces findings from new upper atmospheric radar system for scientific research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds ... baby,s sock that monitors vital signs and alerts ... an infant,s oxygen saturation level drops. But pediatric ... alarm to parents, with no evidence of medical ... devices are marketed aggressively to parents of healthy ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... oncology and dermatology biopharmaceutical company, today is providing ... its previously announced rights offering of up to ... stock and Series C Convertible Preferred Stock to ... As previously announced, the rights offering ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading ... financial results for the fourth quarter and fiscal year of ... Total sales in the fourth quarter of ... 13.6% in USD terms to $77.6 million from $68.3 million ... profit increased by 13.3% to $46.8 million from $41.3 million ...
(Date:2/23/2017)... NEW YORK , Feb. 23, 2017 ... a leading digital health company, and Digital ... telemedicine and remote patient monitoring, announce they are ... DN Telehealth maximizes collaboration compatibility ... extending consultations beyond a physical clinical setting to ...
Breaking Biology Technology: